These results suggest that targeting the Wnt/β-catenin-MITF pathway is a promising strategy to boost the efficacy of anti-PD-1 immunotherapy through potentiation of ferroptosis in MM. This evidence concerns the gene PDCD1 and Miyoshi myopathy.